Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
Insider sale under a pre-established plan: Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported the sale of 354 shares of common stock on 08/26/2025 at a price of $25.44 per share. After the transaction, Berard beneficially owned 134,264 shares, held directly. The filing states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations from restricted stock vesting. The Form 4 is a routine disclosure of a planned sale; no new grants, options, or derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 10,000 shares of BLFS common stock on 08/25/2025 at a weighted average price of $25.53 per share (individual trade prices ranged from $25.46 to $25.63). After the sale, the reporting person beneficially owned 124,618 shares. The Form 4 was signed on 08/27/2025 and discloses the sale as a direct disposition. The filer notes the reported price is a weighted average from multiple transactions and offers to provide the number of shares sold at each price upon request.
Form 144 notice for BioLife Solutions, Inc. (BLFS) reports a proposed sale of 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $255,265 and an approximate sale date of 08/25/2025. The shares were acquired on 03/03/2025 as restricted stock that vested under a registered plan and the payment type is recorded as compensation. The filer reports no securities sold in the past three months and includes the required representation that they are not aware of undisclosed material adverse information.
Casdin-related entities reported a 14.0% stake in BioLife Solutions (BLFS), owning 6,707,165 common shares based on 47,905,265 shares outstanding as of July 31, 2025. The shares are held by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin, who together share voting and dispositive power over the reported shares. The Reporting Persons state the shares were purchased for investment using the Fund's working capital and that no borrowed funds were used other than ordinary working capital borrowings. They state no current plans to pursue corporate control changes but reserve the right to recommend actions or cooperate with others to maximize shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of 500,000 shares of BioLife Solutions, Inc. (BLFS) on 08/15/2025 at a reported price of $24.40 per share. After the transaction, the Master Fund beneficially owned 6,707,165 shares, held indirectly. The Form 4 lists related reporting entities and individuals: Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin, each identified as a director or related to the Master Fund, and signatures are dated 08/21/2025. The filing includes a disclosure that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
BioLife Solutions, Inc. reported the results of its 2025 annual meeting of stockholders held on August 20, 2025. Stockholders of record as of June 23, 2025, holding 47,835,214 shares of common stock, were eligible to vote, and 43,063,037 shares were present or represented by proxy.
All seven director nominees – Roderick de Greef, Catherine Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, Tony Hunt, and Timothy Moore – were elected to serve until the 2026 annual meeting. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,403,856 votes for and 2,060,352 against. In addition, they ratified the Audit Committee’s appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 43,024,019 votes for and 11,169 against.
BioLife Solutions, Inc. (BLFS) Rule 144 notice reports a proposed sale of 500,000 common shares through BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000. The filing states total shares outstanding of 47,905,265. The securities to be sold were acquired in three cash purchases: 250,000 on 07/02/2020, 100,000 on 12/16/2020, and 150,000 on 04/30/2024. The filer discloses prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 and 500,000 shares on 08/11/2025 with stated gross proceeds.
T. Rowe Price Investment Management, Inc. reports holding 4,246,706 shares of BioLife Solutions common stock, representing 8.9% of the class. The filing is a Schedule 13G filed by an investment adviser (classification IA) and indicates sole voting and sole dispositive power over those shares. The filer certifies the securities were acquired and are held in the ordinary course of business and states they were not acquired to change or influence control of the issuer. The filing also includes a declaration denying beneficial ownership in a closing certification.
Casdin-related reporting persons disclosed beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. That stake represents 15.0% of the company based on 47,905,265 shares outstanding as of July 31, 2025. The filing names Casdin Capital, LLC; Casdin Partners Master Fund, L.P.; Casdin Partners GP, LLC; and Eli Casdin as the reporting persons.
The filing states the Fund used its working capital to purchase the shares and did not use borrowed funds except for ordinary working capital borrowing. The Reporting Persons say they currently have no plans to change board composition, management, capitalization or dividend policy but reserve the right to propose or effect such changes and to engage with management and other shareholders about maximizing shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of BioLife Solutions, Inc. (BLFS) common stock on 08/11/2025. The filing shows a reported sale of 500,000 shares at a price of $22.60 per share. The transaction is recorded with transaction code S indicating a disposition.
The filing identifies related reporting entities—Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin—and states the securities are owned directly by the Master Fund and may be indirectly beneficially owned by those entities. After the reported transaction the reporting persons are shown as beneficially owning 7,207,165 shares indirectly.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
